29A Stock Overview
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.42 |
| 52 Week High | US$58.50 |
| 52 Week Low | US$34.10 |
| Beta | 0.82 |
| 11 Month Change | -4.82% |
| 3 Month Change | 3.31% |
| 1 Year Change | -15.69% |
| 33 Year Change | 134.70% |
| 5 Year Change | 158.45% |
| Change since IPO | 313.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -1.2% | -0.02% |
| 1Y | -15.7% | -20.1% | 8.2% |
Return vs Industry: 29A exceeded the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 29A underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 29A volatility | |
|---|---|
| 29A Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 29A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 29A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,761 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
| 29A fundamental statistics | |
|---|---|
| Market cap | €2.10b |
| Earnings (TTM) | €151.46m |
| Revenue (TTM) | €694.82m |
13.9x
P/E Ratio3.0x
P/S RatioIs 29A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29A income statement (TTM) | |
|---|---|
| Revenue | US$723.55m |
| Cost of Revenue | US$340.20m |
| Gross Profit | US$383.35m |
| Other Expenses | US$225.63m |
| Earnings | US$157.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.28 |
| Gross Margin | 52.98% |
| Net Profit Margin | 21.80% |
| Debt/Equity Ratio | 81.9% |
How did 29A perform over the long term?
See historical performance and comparison